News NewsNew Publication – Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis | Sept 28, 2021Press Release – CEM Corporation and AmbioPharm Form U.S. Partnership for GMP Peptide Production | Sept 14, 2021Press Release – AmbioPharm Working with UC Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics | July 20, 2021Blog Post – An Approval for Apellis | June 8, 2021Blog Post – Bivalirudin (“Angiomax”): Rescue Therapy in Covid Cases | May 6, 2021Blog Post – 100 Years of Insulin: A Triumph of Science | May 4, 2021Blog Post – Green Peptide Chemistry and Sustainability Publication | April 20, 2021Blog Post – Streamlining the Path to Peptide Market Supply | March 17, 2021 Blog Post – Peptide Toxin-derived KV1.3 Channel Inhibitor Publication in the British Journal of Pharmacology | March 2, 2021Blog Post – New Cyclic Peptides Review | February 9, 2021AmbioPharm Inc. Announces New Shanghai Campus Opening and European Executive Team Members | January 7, 2021Blog Post – Goodbye 2020: A Peptide Drug Recap and New Webcasts | January 4, 2021Blog Post – Hope on the Horizon: Covid-19 Vaccine Update and Other Relevant Information | December 2, 2020Upsher-Smith & AmbioPharm Announce Partnership Agreement to Develop & Market Corticotropin Injection | August 10, 2020Adalvo and AmbioPharm partner on development & licensing for key peptide products | July 29, 2020AmbioPharm Inc. Expands Peptide Production Helping Fight Against Covid-19 | July 1, 2020
中文